Gastric HER2 testing study (GaTHER): An evaluation of gastric/ gastroesophageal junction cancer testing accuracy in Australia

American Journal of Surgical Pathology

Volumn 36, Issue 4, 2012, Pages 577-582

  Fox, Stephen B ^a   Kumarasinghe, Marian Priyanthi ^b   Armes, Jane E ^c   Bilous, Michael ^e   Cummings, Margaret C ^d   Farshid, Gelareh ^h   Fitzpatrick, Nicole ^f   Francis, Glenn D ^d   McCloud, Philip I ^g   Raymond, Wendy ⁱ   Morey, Adrienne ^g  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b PATHWEST LABORATORY MEDICINE   (Australia)

^c MATER HOSPITAL   (Australia)

^d ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^e Norwest Private Hospital   (Australia)

^f Roche Products Pty Ltd   (Australia)

^g ST VINCENT S HOSPITAL   (Australia)

^h SA Pathology   (Australia)

ⁱ FLINDERS MEDICAL CENTRE   (Australia)

Author keywords

gastric cancer; HER2; immunohistochemistry; in situ hybridization; trastuzumab

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; HER2 PROTEIN, HUMAN; TUMOR MARKER;

ARTICLE; CHROMOSOME 17; CLINICAL TRIAL; COMPARATIVE STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DOSAGE; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; LOWER ESOPHAGUS SPHINCTER; METABOLISM; METHODOLOGY; MULTICENTER STUDY; PATHOLOGY; REPRODUCIBILITY; STOMACH; STOMACH TUMOR;

CHROMOSOMES, HUMAN, PAIR 17; ESOPHAGOGASTRIC JUNCTION; GENE DOSAGE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; RECEPTOR, ERBB-2; REPRODUCIBILITY OF RESULTS; STOMACH; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84859107754     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e318244adbb     Document Type: Article

References (25)

1. Albarello L, Pecciarini L, Doglioni C. HER2 testing in gastric cancer. Adv Anat Pathol. 2011;18:53-59.
2. Altman DG. Practical Statistics for Medical Research. Chapman & Hall/CRC Texts in Statistical Science, Boca Raton: FL; 1991.
3. Australian Institute of Health and Welfare and Australasian Association of Cancer Registries. Cancer in Australia: an overview, 2008 [Australian Institute of Health and Welfare web site]. Available at: http://www.aihw.gov.au/ publications/can/ca08/ca08.pdf. Accessed June 15, 2009.
4. Bang Y, Chung H, Xu J, et al. Pathological features of advanced gastric cancer (GC): relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial. J Clin Oncol. 2009;27:15s. (suppl; abstract 4556).
5. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687-697.
6. Bilous M, Osamura RY, Rüschoff J, et al. Comment: HER-2 amplification is highly homogenous in gastric cancer. Hum Pathol. 2010;41:304-305.
7. Boers JE, Meeuwissen H, Methorst N. HER2 status in gastrooesophageal adenocarcinomas assessed by two rabbit monoclonal antibodies (SP3 and 4B5) and two in situ hybridization methods (FISH and SISH). Histopathology. 2011;58:383-394.
8. Farshid G, Armes JE, Bell R, et al. Establishment of the Australian in situ hybridization program for the assessment of HER2 amplification in breast cancer: a model for the introduction of new biomarkers into clinical practice. Diagn Mol Pathol. 2010; 19:187-193.
9. Francis GD, Dimech M, Giles L, et al. Frequency and reliability of oestrogen receptor, progesterone receptor and HER2 in breast carcinoma determined by immunohistochemistry in Australasia: results of the RCPA Quality Assurance Program. J Clin Pathol. 2007;60:1277-1283.
10. Gaca JG, Petersen RP, Peterson BL, et al. Pathologic nodal status predicts disease-free survival after neoadjuvant chemoradiation for gastroesophageal junction carcinoma. Ann Surg Oncol. 2006;13: 340-346.
11. Garcia M, Jemal A, Ward EM, et al. Global Cancer Facts & Figures 2007. Atlanta, GA: American Cancer Society; 2007.
12. Grabsch H, Sivakumar S, Gray S, et al. HER2 expression in gastric cancer: rare, heterogeneous and of no prognostic value- conclusions from 924 cases of two independent series. Cell Oncol. 2010;32:57-65.
13. Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol. 2008;19:1523-1529.
14. Hofmann M, Stoss O, Shi D, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology. 2008;52:797-805.
15. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006;24:2137-2150.
16. Kusano C, Gotoda T, Khor CJ, et al. Changing trends in the proportion of adenocarcinoma of the esophagogastric junction in a large tertiary referral center in Japan. J Gastroenterol Hepatol. 2008;23:1662-1665.
17. Lee S, de Boer WB, Fermoyle S, et al. HER-2 testing in gastric carcinoma: issues related to heterogeneity in biopsies and resections. Histopathology. (In press).
18. Nowak JA, Moncur AT, Morrison CD, et al. On behalf of the Molecular Oncology Committee. Survey. ISH, a Participant Summary College of American Pathologists, Northfield: IL; 2010.
19. Okines AF, Cunningham D. Trastuzumab in gastric cancer. Eur J Cancer. 2010;46:1949-1959.
20. Paik S, Bryant J, Tan-Chiu E, et al. Real-world performance of HER2 testing-National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst. 2002;94:852-854.
21. Power DG, Kelsen DP, Shah MA. Advanced gastric cancer-slow but steady progress. Cancer Treat Rev. 2010;36:384-392.
22. Roche PC, Suman VJ, Jenkins RB, et al. Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. J Natl Cancer Inst. 2002;94:855-857.
23. Rüschoff J, Dietel M, Baretton G, et al. HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch. 2010;457:299-307.
24. Salto-Tellez M, Yau EX, Yan B, et al. Where and by whom should gastric cancer HER2/neu status be assessed?: lessons from breast cancer. Arch Pathol Lab Med. 2011;135:693-695.
25. Schouten HJA. Measuring pairwise interobserver agreement when all subjects are judged by the same observers. Stat Neerl. 1982; 36:45-61.